Curcumin in Ophthalmology: Mechanisms, Challenges, and Emerging Opportunities DOI Creative Commons
Adriana Ribeiro, Daniele Martins de Lima Oliveira, Helena Cabral-Marques

et al.

Molecules, Journal Year: 2025, Volume and Issue: 30(3), P. 457 - 457

Published: Jan. 21, 2025

Ocular diseases affecting the anterior and posterior segments of eye are major causes global vision impairment. Curcumin, a natural polyphenol, exhibits anti-inflammatory, antioxidant, antibacterial, neuroprotective properties, making it promising candidate for ocular therapy. However, its clinical use is hindered by low aqueous solubility, poor bioavailability, rapid systemic elimination. This review comprehensively highlights advances in curcumin delivery systems aimed at overcoming these challenges. Emerging platforms, including proniosomal gels, transferosomes, cyclodextrin complexes, have improved permeability, retention. Nanoparticle-based carriers, such as hybrid hydrogels biodegradable nanoparticles, enable sustained release targeted delivery, supporting treatments segment like diabetic retinopathy age-related macular degeneration. For conditions, keratitis dry syndrome, cyclodextrin-based complexes mucoadhesive enhance corneal permeability drug Mechanistically, modulates key pathways, NF-κB TLR4, reducing oxidative stress, angiogenesis, apoptosis. strategies photodynamic therapy approaches broaden their application to eyelid conditions neuroinflammatory diseases. These advancements address curcumin’s pharmacokinetic limitations, translation into ophthalmic therapies. work underscores potential disease management advocates trials validate safety, efficacy, therapeutic relevance.

Language: Английский

Curcumin in Ophthalmology: Mechanisms, Challenges, and Emerging Opportunities DOI Creative Commons
Adriana Ribeiro, Daniele Martins de Lima Oliveira, Helena Cabral-Marques

et al.

Molecules, Journal Year: 2025, Volume and Issue: 30(3), P. 457 - 457

Published: Jan. 21, 2025

Ocular diseases affecting the anterior and posterior segments of eye are major causes global vision impairment. Curcumin, a natural polyphenol, exhibits anti-inflammatory, antioxidant, antibacterial, neuroprotective properties, making it promising candidate for ocular therapy. However, its clinical use is hindered by low aqueous solubility, poor bioavailability, rapid systemic elimination. This review comprehensively highlights advances in curcumin delivery systems aimed at overcoming these challenges. Emerging platforms, including proniosomal gels, transferosomes, cyclodextrin complexes, have improved permeability, retention. Nanoparticle-based carriers, such as hybrid hydrogels biodegradable nanoparticles, enable sustained release targeted delivery, supporting treatments segment like diabetic retinopathy age-related macular degeneration. For conditions, keratitis dry syndrome, cyclodextrin-based complexes mucoadhesive enhance corneal permeability drug Mechanistically, modulates key pathways, NF-κB TLR4, reducing oxidative stress, angiogenesis, apoptosis. strategies photodynamic therapy approaches broaden their application to eyelid conditions neuroinflammatory diseases. These advancements address curcumin’s pharmacokinetic limitations, translation into ophthalmic therapies. work underscores potential disease management advocates trials validate safety, efficacy, therapeutic relevance.

Language: Английский

Citations

0